别嘌醇与非布司他预防老年人新发肾脏疾病的比较效果:Medicare理赔数据分析
该回顾性队列研究利用2006-2012年Medicare理赔数据,比较别嘌醇与非布司他预防老年人新发肾脏疾病的效果。经5:1倾向匹配Cox回归分析,别嘌醇使用与新发肾脏疾病风险降低相关(HR 0.61,95%CI 0.49-0.77),且别嘌醇剂量越高风险越低,敏感性分析结果一致。
要点
- 别嘌醇较非布司他降低新发肾脏疾病风险(HR 0.61,95%CI 0.49-0.77)。
- 别嘌醇剂量≥300 mg/day者风险最低(HR 0.48,95%CI 0.41-0.55)。
- 别嘌醇粗发生率192/1000人年,低于非布司他的338/1000人年。
核心结论
- 在老年患者中,别嘌醇使用与新发肾脏疾病风险低于非布司他相关。
研究设计与样本
- 回顾性队列研究,使用2006-2012年Medicare理赔数据,纳入新使用别嘌醇或非布司他的患者,基线期183天未用任一药物。
- 采用5:1倾向匹配Cox回归分析比较新发肾脏疾病风险,并以多变量调整回归模型进行敏感性分析。
主要发现
- 26 443例患者中共31 465次新治疗 episode,其中8570次发生新发肾脏疾病。
- 别嘌醇粗发生率为192/1000人年,非布司他为338/1000人年。
- 别嘌醇日剂量<200、200-299、≥300 mg/day的粗发生率分别为238、176、155/1000人年;非布司他40和80 mg/day分别为341和326/1000人年。
- 倾向匹配分析中,与非布司他相比,别嘌醇新发肾脏疾病HR为0.61(95%CI 0.49-0.77)。
- 与非布司他40 mg/day相比,别嘌醇<200、200-299、≥300 mg/day的HR分别为0.75(95%CI 0.65-0.86)、0.61(95%CI 0.52-0.73)、0.48(95%CI 0.41-0.55)。
临床怎么用
- 在老年高尿酸血症患者中,选择别嘌醇可能较非布司他更有利于降低新发肾脏疾病风险。
- 别嘌醇的肾脏保护作用可能呈剂量依赖性,但需结合患者耐受性个体化调整剂量。
局限性
- 研究为回顾性理赔数据分析,可能存在未测量混杂因素。
- 原文未报告具体局限性描述。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess the comparative effectiveness of allopurinol versus febuxostat for preventing incident renal disease in elderly. METHODS: In a retrospective cohort study using 2006-2012 Medicare claims data, we included patients newly treated with allopurinol or febuxostat (baseline period of 183 days without either medication). We used 5:1 propensity-matched Cox regression analyses to compare the HR of incident renal disease with allopurinol use (and dose) versus febuxostat (reference). Sensitivity analyses included multivariable-adjusted regression models. RESULTS: There were 31 465 new allopurinol or febuxostat treatment episodes in 26 443 patients; 8570 ended in incident renal disease. Crude rates of incident renal disease per 1000 person-years were 192 with allopurinol versus 338 with febuxostat. Crude rates of incident renal disease per 1000 person-years were lower with higher daily dose: allopurinol <200, 200-299 and ≥300 mg/day with 238, 176 and 155; and febuxostat 40 and 80 mg/day with 341 and 326, respectively. In propensity-matched analyses, compared with febuxostat, allopurinol use was associated with lower HR of incident renal disease, 0.61 (95% CI 0.49 to 0.77). Compared with febuxostat 40 mg/day, allopurinol doses <200, 200-299 and ≥300 mg/day were associated with lower HR of incident renal disease, 0.75 (95% CI 0.65 to 0.86), 0.61 (95% CI 0.52 to 0.73) and 0.48 (95% CI 0.41 to 0.55), respectively. Sensitivity analyses using multivariable-adjusted regression confirmed these findings. CONCLUSIONS: Allopurinol was associated with a lower risk of incident renal disease in elderly patients than febuxostat. Future studies need to examine the mechanism of this potential renal benefit of allopurinol.
引用
- Singh JA, Cleveland JD. Comparative effectiveness of allopurinol versus febuxostat for preventing incident renal disease in older adults: an analysis of Medicare claims data. Ann Rheum Dis. 2017. PMID: 28584186. doi:10.1136/annrheumdis-2017-211210
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。